ÀǾàǰ °³¹ß ¹× Á¦Á¶ ¼öʱâ°ü ½ÃÀå ¿¹Ãø(-2030³â) : ¼­ºñ½º À¯Çüº°, ºÐÀÚ À¯Çüº°, Á¦Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¼¼°è ºÐ¼®
Pharmaceutical Contract Development & Manufacturing Organization Market Forecasts to 2030 - Global Analysis By Service Type, Molecule Type, Dosage Form, Application, End User and By Geography
»óǰÄÚµå : 1494860
¸®¼­Ä¡»ç : Stratistics Market Research Consulting
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,150 £Ü 5,734,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,253,000
PDF (2-5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,350 £Ü 8,773,000
PDF & Excel (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,362,000
PDF & Excel (Global Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 10ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Stratistics MRC¿¡ µû¸£¸é, ¼¼°è ÀǾàǰ °³¹ß ¹× Á¦Á¶ ¼öʱâ°ü ½ÃÀåÀº 2024³â 2,432¾ï 9,000¸¸ ´Þ·¯ ±Ô¸ðÀ̸ç, 2030³â¿¡´Â 3,546¾ï 8,000¸¸ ´Þ·¯·Î ¿¬Æò±Õ 8.4%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀǾàǰ °³¹ß ¹× Á¦Á¶ ¼öʱâ°ü(CDMO)Àº Á¦¾àȸ»ç ¹× »ý¸í°øÇÐ ±â¾÷¿¡ Á¾ÇÕÀûÀÎ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â Àü¹® ±â¾÷ÀÔ´Ï´Ù. CDMO´Â Ãʱâ Á¦Ç° ÄÁ¼ÁºÎÅÍ »ó¾÷Àû »ý»ê¿¡ À̸£±â±îÁö ÀǾàǰ °³¹ß ¹× »ý»êÀÇ Àü °úÁ¤À» ¾Æ¿ì¸£¸ç, Á¦Çü °³¹ß, ºÐ¼® Å×½ºÆ®, °øÁ¤ ÃÖÀûÈ­, ±ÔÁ¦ Áؼö µîÀÇ Àü¹® Áö½ÄÀ» º¸À¯Çϰí ÀÖ½À´Ï´Ù. CDMO´Â ÀǾàǰ °³¹ß ¹× Á¦Á¶ÀÇ ´Ù¾çÇÑ Ãø¸éÀ» ¾Æ¿ô¼Ò½ÌÇÔÀ¸·Î½á °í°´Àº CDMOÀÇ Àü¹® ¿ª·®°ú ÀÎÇÁ¶óÀÇ ÇýÅÃÀ» ´©¸®¸é¼­ ÇÙ½É ¿ª·®¿¡ ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù.

±¹°¡À§»ýÀ§¿øÈ¸(NHC)¿¡ µû¸£¸é, Áß±¹¿¡´Â ¸¸¼ºÁúȯÀ» ¾Î°í ÀÖ´Â ³ëÀÎÀÌ 1¾ï 8,000¸¸ ¸í ÀÌ»óÀ̸ç, ±× Áß 75%´Â ¿©·¯ °¡Áö ¸¸¼ºÁúȯÀ» ¾Î°í ÀÖ½À´Ï´Ù.

¼ºÀåÇÏ´Â ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå

¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀÇ È®´ë´Â Àü¹® Áö½Ä°ú ÀÎÇÁ¶ó¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ¿© PCDMOÀÇ È®ÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. CDMO´Â Á¦¾à»çÀÇ ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­Çϰí, ºñ¿ëÀ» Àý°¨Çϸç, À§ÇèÀ» ÁÙ¿© Çõ½ÅÀ» ÃËÁøÇϰí, »õ·Î¿î Ä¡·áÁ¦ÀÇ ½ÃÀå Ãâ½Ã ½Ã°£À» ´ÜÃàÇÏ´Â µî ¹ÙÀÌ¿ÀÀǾàǰÀÇ °íÀ¯ÇÑ ¿ä±¸»çÇ×À» ÃæÁ·ÇÏ´Â ¸ÂÃãÇü ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ´ÜÃàÇÕ´Ï´Ù. ¹ÙÀÌ¿ÀÀǾàǰÀÌ ½ÃÀå °³Ã´ÀÇ ÁÖ¿ªÀ¸·Î ¶°¿À¸£¸é¼­ CDMO´Â °³¹ß ¹× »ó¾÷È­¸¦ Áö¿øÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ÀÌ ºÎ¹®ÀÇ ¼ºÀå ±Ëµµ¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç ¹× ÄÄÇöóÀ̾𽺠±âÁØ

CDMOÀÇ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç°ú ÄÄÇöóÀ̾𽺠±âÁØÀº Á¦Ç°ÀÇ Ç°Áú, ¾ÈÀü¼º, À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇØ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±âÁØÀº ¿î¿µ ºñ¿ëÀÇ Áõ°¡, ½ÃÀå °³Ã´ ±â°£ÀÇ Àå±âÈ­, Áß¼Ò±â¾÷ÀÇ ÁøÀÔÀ庮À» Çü¼ºÇÏ¿© ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ±ÔÁ¦ Áؼö¿¡ ¸¹Àº ÀÚ¿øÀÌ ¼Ò¿äµÇ´Â °æ¿ì°¡ ¸¹À¸¸ç, ÀÌ´Â ¼­ºñ½º ¹× Á¦Ç° °¡°Ý »ó½ÂÀ¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾ö°ÝÇÑ ±ÔÁ¦´Â ±â¼ú Çõ½ÅÀ» ¾ïÁ¦ÇÏ°í ½ÃÀå ¼ö¿ä¿¡ ÀûÀÀÇÒ ¼ö ÀÖ´Â À¯¿¬¼ºÀ» Á¦ÇÑÇÏ¿© Àüü ½ÃÀåÀÇ ¼ºÀå°ú °æÀïÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü¹® Áö½Ä¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

Á¦¾à»çµéÀÌ ¿ÜºÎ Àü¹® Áö½ÄÀ» Ȱ¿ëÇϸ鼭 ÇÙ½É ¿ª·®¿¡ ÁýÁßÇϰíÀÚ ÇÏ´Â °¡¿îµ¥, CDMO´Â Á¦Çü °³¹ß, Á¦Á¶, Æ÷Àå µî Àü¹® ¼­ºñ½º¸¦ Á¦°øÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ÃֽŠÀǾàǰ °³¹ßÀÇ º¹À⼺, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, ºñ¿ë È¿À²ÀûÀÎ Àü·«ÀÇ Çʿ伺¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖÀ¸¸ç, CDMO´Â Á¦Çü °³¹ß, ºÐ¼® Å×½ºÆ®, Á¦Á¶ ¹× Æ÷ÀåÀ» Æ÷ÇÔÇÑ ±¤¹üÀ§ÇÑ ¼­ºñ½º¸¦ Á¦°øÇÏ¿© Á¦¾à»ç°¡ Á¦Ç° ÆÄÀÌÇÁ¶óÀÎÀ» °¡¼ÓÈ­Çϰí Çõ½ÅÀûÀÎ Ä¡·áÁ¦¸¦ È¿À²ÀûÀ¸·Î ½ÃÀå¿¡ Ãâ½ÃÇÒ ¼ö ÀÖµµ·Ï µ½°í ½ÃÀå È®´ë¸¦ ÃËÁøÇÕ´Ï´Ù. ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

°¡°Ý ¾Ð·Â

CDMOÀÇ °¡°Ý ¾Ð·ÂÀº °æÀï ½ÉÈ­, ±ÔÁ¦ º¯°æ, ¿øÀÚÀç ¹× ÀΰǺñ »ó½ÂÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾Ð·ÂÀº Á¾Á¾ °¡°Ý Ç϶ô Ãß¼¼·Î À̾îÁ® ¼öÀÍ·üÀ» ¾Ð¹ÚÇÏ°í ±â¼ú Çõ½Å°ú »ç¾÷ È®Àå¿¡ ´ëÇÑ ÅõÀÚ¸¦ ¹æÇØÇÕ´Ï´Ù. ±× °á°ú CDMO´Â ¼öÀͼºÀ» À¯ÁöÇϱâ À§ÇØ °í±ººÐÅõÇϰí ÷´Ü ±â¼ú ¹× ÀÎÇÁ¶ó ¾÷±×·¹À̵忡 ÅõÀÚÇÒ ¼ö ¾ø°Ô µË´Ï´Ù. ÀÌ·¯ÇÑ ÅõÀÚ ¾ïÁ¦ »çÀÌŬÀº ½Å¾à °³¹ßÀ» ¹æÇØÇϰí ÁøÈ­ÇÏ´Â ÀÇ·á ¼ö¿ä¿¡ ´ëÀÀÇÏ´Â ¾÷°èÀÇ ´É·ÂÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

COVID-19´Â ÀǾàǰ °³¹ß ¹× Á¦Á¶ ¼öʱâ°ü ½ÃÀå¿¡ ´Ù¾çÇÑ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ¹é½Å ¹× Ä¡·áÁ¦¿Í °°Àº ƯÁ¤ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí Á¦Á¶ Áö¿øÀ» À§ÇØ CDMO¿¡ ´ëÇÑ ¾Æ¿ô¼Ò½ÌÀÌ Áõ°¡ÇÑ ¹Ý¸é, ÆÒµ¥¹ÍÀº °ø±Þ¸ÁÀ» È¥¶õ¿¡ ºü¶ß¸®°í ÀÓ»ó½ÃÇè ¹× ±ÔÁ¦ ÇÁ·Î¼¼½º¸¦ Áö¿¬½ÃÄ×½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î ÆÒµ¥¹ÍÀº ¹ÎøÇϰí ź·ÂÀûÀÎ Á¦Á¶ ´É·ÂÀÇ Á߿伺À» °­Á¶ÇÏ°í ¹Ì·¡ÀÇ È¥¶õÀ» ¿ÏÈ­Çϱâ À§ÇÑ ±â¼ú ¹× ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇß½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È °³¹ß ¼­ºñ½º ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°³¹ß¼­ºñ½º ºÎ¹®Àº ¾çÈ£ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °³¹ß ¼­ºñ½º ÀǾàǰ °³¹ß ¹× Á¦Á¶ ¼öʱâ°ü(CDMO)Àº ½Å¾à °³¹ßºÎÅÍ ÀÓ»ó½ÃÇè±îÁö Á¾ÇÕÀûÀÎ Áö¿øÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¼­ºñ½º¿¡´Â Á¦Çü °³¹ß, ºÐ¼®¹ý °³¹ß, ¾ÈÁ¤¼º ½ÃÇè, ÀǾàǰ Çã°¡ ½Åû µîÀÌ Æ÷ÇԵǸç, CDMO´Â Á¦¾àȸ»ç°¡ °³¹ß ±â°£À» ´ÜÃàÇÏ°í ºñ¿ëÀ» Àý°¨Çϸç Àü¹® Áö½ÄÀ» Ȱ¿ëÇÒ ¼ö ÀÖµµ·Ï Çϸç, ÄÁ¼Á¿¡¼­ ÀÓ»ó Æò°¡¿¡ À̸£±â±îÁö ÀǾàǰ Èĺ¸¹°ÁúÀÇ È¿À²ÀûÀÌ°í ±ÔÁ¤ ÁؼöÀûÀÎ ÁøÇàÀ» º¸ÀåÇÕ´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ºÐ¾ß´Â »ý¸í°øÇÐ ±â¾÷ ºÎ¹®ÀÔ´Ï´Ù.

¹ÙÀÌ¿ÀÅØ ±â¾÷ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CDMO´Â ¹ÙÀÌ¿ÀÅØ ±â¾÷¿¡ ÀǾàǰ °³¹ß ¹× Á¦Á¶¸¦ À§ÇÑ Àü¹® ¼­ºñ½º¸¦ Á¦°øÇϸç, CDMO´Â Á¦ÇüÈ­, ÀÓ»ó½ÃÇè Áö¿ø, ´ë±Ô¸ð Á¦Á¶ µîÀÇ ºÎ¹®¿¡¼­ Àü¹®¼ºÀ» º¸À¯Çϰí ÀÖ½À´Ï´Ù. Àü¹®¼ºÀ» º¸À¯Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾÷¹«¸¦ ¾Æ¿ô¼Ò½ÌÇÔÀ¸·Î½á »ý¸í°øÇÐ ±â¾÷µéÀº Çõ½Å¿¡ ÁýÁßÇÒ ¼ö ÀÖ°í, CDMOÀÇ Ã·´Ü ±â¼ú ¹× ±ÔÁ¦ Áؼö Àü¹® Áö½ÄÀ» Ȱ¿ëÇÏ¿© »õ·Î¿î Ä¡·á¹ýÀ» ½ÃÀå¿¡ Ãâ½ÃÇÏ´Â ½Ã°£À» ´ÜÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

°¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷ÀÇ ±Þ¼ÓÇÑ ¼ºÀå, ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» ã´Â À¯·´ ¹× ¹Ì±¹ ±â¾÷ÀÇ ¾Æ¿ô¼Ò½Ì Ãß¼¼ Áõ°¡, Àú·ÅÇÑ ºñ¿ëÀ¸·Î ¼÷·ÃµÈ ÀηÂÀÇ °¡¿ë¼º µîÀÌ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ý¸í°úÇÐ ºÎ¹®À» ÃËÁøÇϱâ À§ÇÑ ¿ìÈ£ÀûÀÎ ±ÔÁ¦ ȯ°æ°ú Á¤ºÎÀÇ ³ë·ÂÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¦³×¸¯ ÀǾàǰ°ú »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀº ±¤¹üÀ§ÇÑ °³¹ß ¹× Á¦Á¶ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â CDMOÀÇ Àü·«Àû °ÅÁ¡ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª:

¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì°¡ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Çõ½Å, ǰÁú ¹× È¿À²¼º¿¡ ÁßÁ¡À» µÐ ºÏ¹Ì CDMO´Â ÀǾàǰ °³¹ß, Á¦Á¶, Æ÷Àå ¹× °ø±Þ¸Á °ü¸® Àü¹Ý¿¡ °ÉÄ£ ¿£µå Åõ ¿£µå ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ Áö¿ªÀº °­·ÂÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ¼÷·ÃµÈ ÀηÂ, ÷´Ü ÀÎÇÁ¶óÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖÀ¸¸ç, ±¹³»¿Ü °í°´µéÀ» ²ø¾îµéÀ̰í ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº ÁøÈ­ÇÏ´Â »ê¾÷ ¼ö¿ä¿¡ ´ëÀÀÇϱâ À§ÇØ ²÷ÀÓ¾øÀÌ ¿¬±¸°³¹ß°ú ±â¼ú ¹ßÀü¿¡ ÅõÀÚÇÏ¿© ½ÃÀå °æÀï·Â°ú Áö¼Ó°¡´É¼ºÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

¹«·á ¸ÂÃãÇü ¼­ºñ½º:

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÈ­ ¿É¼Ç Áß Çϳª¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

Á¦4Àå Porter's Five Forces ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ÀǾàǰ °³¹ß ¹× Á¦Á¶ ¼öʱâ°ü ½ÃÀå : ¼­ºñ½º À¯Çüº°

Á¦6Àå ¼¼°èÀÇ ÀǾàǰ °³¹ß ¹× Á¦Á¶ ¼öʱâ°ü ½ÃÀå : ºÐÀÚ À¯Çüº°

Á¦7Àå ¼¼°èÀÇ ÀǾàǰ °³¹ß ¹× Á¦Á¶ ¼öʱâ°ü ½ÃÀå : Á¦Çüº°

Á¦8Àå ¼¼°èÀÇ ÀǾàǰ °³¹ß ¹× Á¦Á¶ ¼öʱâ°ü ½ÃÀå : ¿ëµµº°

Á¦9Àå ¼¼°èÀÇ ÀǾàǰ °³¹ß ¹× Á¦Á¶ ¼öʱâ°ü ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ¼¼°èÀÇ ÀǾàǰ °³¹ß ¹× Á¦Á¶ ¼öʱâ°ü ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä °³¹ß

Á¦12Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

According to Stratistics MRC, the Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market is accounted for $243.29 billion in 2024 and is expected to reach $354.68 billion by 2030 growing at a CAGR of 8.4% during the forecast period. A Pharmaceutical Contract Development & Manufacturing Organization (CDMO) is a specialized corporation that provides comprehensive services to pharmaceutical and biotechnology companies. These services encompass the entire drug development and manufacturing process, from initial product concept to commercial production. CDMOs offer expertise in formulation development, analytical testing, process optimization, and regulatory compliance. They enable clients to outsource various aspects of drug development and production, allowing them to focus on core competencies while benefiting from the CDMO's specialized capabilities and infrastructure.

According to the National Health Commission (NHC), China has over 180 million elderly citizens suffering from chronic diseases, of which 75% have more than one.

Market Dynamics:

Driver:

Rising biopharmaceuticals market

The rising biopharmaceuticals market fuels demand for specialized expertise and infrastructure, driving the expansion of PCDMOs. These organizations offer tailored solutions for drug development, manufacturing, and testing, catering to the unique requirements of biopharmaceuticals. CDMOs streamline processes, reduce costs, and mitigate risks for pharmaceutical companies, fostering innovation and accelerating time-to-market for new therapies. As biopharmaceuticals continue to dominate the market, CDMOs play a pivotal role in supporting their development and commercialization efforts, fueling the growth trajectory of the sector.

Restraint:

Stringent regulatory requirements & compliance standards

Stringent regulatory requirements and compliance standards in CDMOs are essential to ensure product quality, safety, and efficacy. These standards can hamper market growth by increasing operational costs, lengthening development timelines, and creating barriers to entry for smaller companies. Compliance efforts often require substantial resources, leading to higher prices for services and products. Additionally, stringent regulations may deter innovation and limit flexibility in adapting to market demands, thus impeding overall market expansion and competitiveness.

Opportunity:

Growing demand for specialized expertise

As pharmaceutical companies seek to focus on core competencies while leveraging external expertise, CDMOs play a crucial role in providing specialized services such as formulation development, manufacturing, and packaging. This trend is fuelled by the complexities of modern drug development, stringent regulatory requirements, and the need for cost-effective strategies. CDMOs provide a range of services including formulation development, analytical testing, manufacturing, and packaging, allowing pharmaceutical companies to accelerate their product pipelines and bring innovative treatments to market efficiently, thereby propelling market expansion.

Threat:

Pricing pressures

Pricing pressures in CDMOs arise due to increased competition, regulatory changes, and rising costs of raw materials and labor. These pressures often lead to downward pricing trends, squeezing profit margins and hindering investment in innovation and expansion. Consequently, CDMOs may struggle to maintain profitability and may be unable to invest in advanced technologies or infrastructure upgrades. This cycle of constrained investment can impede the development of new drugs and limit the industry's ability to meet evolving healthcare needs.

Covid-19 Impact

The covid-19 pandemic has had mixed impacts on the pharmaceutical contract development & manufacturing organization (CDMO) market. While the demand for certain pharmaceutical products, such as vaccines and treatments, surged, leading to increased outsourcing to CDMOs for manufacturing support, the pandemic also disrupted supply chains and delayed clinical trials and regulatory processes. Overall, the pandemic emphasized the importance of agile and resilient manufacturing capabilities, driving investment in technology and infrastructure to mitigate future disruptions.

The development services segment is expected to be the largest during the forecast period

The development services segment is estimated to have a lucrative growth. A pharmaceutical contract development & manufacturing organization in development services provides comprehensive support from drug discovery to clinical trials. These services include formulation development, analytical method development, stability studies, and regulatory submissions. CDMOs enable pharmaceutical companies to accelerate development timelines, reduce costs, and access specialized expertise, ensuring efficient and compliant progression of drug candidates from concept to clinical evaluation.

The biotechnology companies segment is expected to have the highest CAGR during the forecast period

The biotechnology companies segment is anticipated to witness the highest CAGR growth during the forecast period. CDMOs provide biotechnology companies with specialized services for drug development and production. They offer expertise in areas like formulation, clinical trial support, and large-scale manufacturing. By outsourcing these tasks, biotech firms can focus on innovation and reduce time-to-market for new therapies, benefiting from CDMOs' advanced technologies and regulatory compliance expertise.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Rapidly expanding pharmaceutical and biotechnology industries, increasing outsourcing trends from Western companies seeking cost-effective solutions, and the availability of skilled labor at lower costs are key drivers. Additionally, favourable regulatory environments and government initiatives to promote the life sciences sector further boost market growth. With a burgeoning demand for generic drugs and biologics, the Asia Pacific region is becoming a strategic hub for CDMOs offering a wide range of development and manufacturing services.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. With a focus on innovation, quality, and efficiency, North American CDMOs offer end-to-end solutions spanning drug development, manufacturing, packaging, and supply chain management. The region benefits from a strong regulatory framework, skilled workforce, and advanced infrastructure, attracting both domestic and international clients. Key players constantly invest in R&D and technological advancements to meet evolving industry demands, ensuring competitiveness and sustainability in the market.

Key players in the market

Some of the key players profiled in the Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market include Lonza Group, Catalent Inc., WuXi AppTec, Samsung Biologics, Boehringer Ingelheim BioXcellence, Parexel International, Thermo Fisher Scientific, Siegfried Holding AG, Fujifilm Diosynth Biotechnologies, Recipharm AB, Albany Molecular Research Inc. (AMRI), Piramal Pharma Solutions, Charles River Laboratories, Ajinomoto Bio-Pharma Services, Alcami Corporation, Cambrex Corporation, Hovione, Fareva, Sartorius Stedim BioOutsource, Micron Technologies.

Key Developments:

In June 2023, FUJIFILM Corporation launched a commercial office in Tokyo to provide enhanced sales support and customer service for Contract Development and Manufacturing services for Biologics and Advanced Therapies to Asia-based pharmaceutical and biotechnology companies.

In April 2023, Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, has an agreement with ABL Bio, a pioneering Korean biologics company with a focus on bispecific antibodies for immuno-oncology and neurodegenerative diseases. The collaboration agreement between Lonza and ABL Bio supports the development and manufacturing of ABL Bio's new bispecific antibody product.

Service Types Covered:

Molecule Types Covered:

Dosage Forms Covered:

Applications Covered:

End Users Covered:

Regions Covered:

What our report offers:

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Table of Contents

1 Executive Summary

2 Preface

3 Market Trend Analysis

4 Porters Five Force Analysis

5 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market, By Service Type

6 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market, By Molecule Type

7 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market, By Dosage Form

8 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market, By Application

9 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market, By End User

10 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market, By Geography

11 Key Developments

12 Company Profiling

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â